GSK3B - Wiki-MPM

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	DRD3	dopamine receptor D3	Dopamine receptors G alpha (i) signalling events	Ziprasidone Cabergoline Ropinirole Dihydroergotamine Olanzapine Clozapine Sulpiride Loxapine Remoxipride Pramipexole Chlorpromazine Buspirone Haloperidol Amoxapine Lisuride Apomorphine Flupentixol Dopamine Ergoloid mesylate Pimozide Domperidone Pergolide Bromocriptine Quetiapine Levodopa Aripiprazole Chlorprothixene Paliperidone Yohimbine Methotrimeprazine Iloperidone Rotigotine Norclozapine Cariprazine Mianserin Asenapine Amisulpride Sarizotan Sumanirole Nandrolone decanoate Captodiame AS-8112 Blonanserin Pipamperone Tianeptine Dihydro-alpha-ergocryptine Epicriptine Pardoprunox Piribedil Tiapride Dihydroergocristine Aripiprazole lauroxil
	ACLY	ATP citrate lyase	ChREBP activates metabolic gene expression Neutrophil degranulation Fatty acyl-CoA biosynthesis	Bempedoic acid
	ACSBG1	acyl-CoA synthetase bubblegum family member 1	Synthesis of very long-chain fatty acyl-CoAs	2-(6-HYDROXY-1,3-BENZOTHIAZOL-2-YL)-1,3-THIAZOL-4(5H)-ONE
	ACTL6B	actin like 6B	RMTs methylate histone arginines RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF)
	ADAP1	ArfGAP with dual PH domains 1	Nuclear signaling by ERBB4
	ADIRF	adipogenesis regulatory factor	Transcriptional regulation of white adipocyte differentiation
	AKAP11	A-kinase anchoring protein 11
	AKT1	AKT serine/threonine kinase 1	Activation of BAD and translocation to mitochondria PIP3 activates AKT signaling PIP3 activates AKT signaling Downregulation of ERBB2:ERBB3 signaling Translocation of SLC2A4 (GLUT4) to the plasma membrane Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation MTOR signalling AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the nucleus Negative regulation of the PI3K/AKT network eNOS activation AKT-mediated inactivation of FOXO1A Integrin signaling Deactivation of the beta-catenin transactivating complex CD28 dependent PI3K/Akt signaling Co-inhibition by CTLA4 G beta:gamma signalling through PI3Kgamma Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA KSRP (KHSRP) binds and destabilizes mRNA VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 RAB GEFs exchange GTP for GDP on RABs RUNX2 regulates genes involved in cell migration Regulation of PTEN stability and activity Extra-nuclear estrogen signaling Negative regulation of NOTCH4 signaling FLT3 Signaling Regulation of localization of FOXO transcription factors Estrogen-dependent nuclear events downstream of ESR-membrane signaling KEAP1-NFE2L2 pathway SARS-CoV-2 targets host intracellular signalling and regulatory pathways Mitochondrial unfolded protein response (UPRmt) High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Mechanical load activates signaling by PIEZO1 and integrins in osteocytes	ATP Arsenic trioxide Genistein Inositol 1,3,4,5-Tetrakisphosphate Resveratrol Archexin Enzastaurin Perifosine N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine	PTEN hamartoma tumor syndrome (PHTS), including: Cowden syndrome; Bannayan-Riley-Ruvalcaba syndrome; Proteus syndrome; Proteus-like syndrome
	AKT2	AKT serine/threonine kinase 2	Activation of BAD and translocation to mitochondria PIP3 activates AKT signaling PIP3 activates AKT signaling Downregulation of ERBB2:ERBB3 signaling Translocation of SLC2A4 (GLUT4) to the plasma membrane Activation of AKT2 PDE3B signalling Inhibition of TSC complex formation by PKB AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the nucleus Negative regulation of the PI3K/AKT network AKT-mediated inactivation of FOXO1A Deactivation of the beta-catenin transactivating complex CD28 dependent PI3K/Akt signaling Co-inhibition by CTLA4 G beta:gamma signalling through PI3Kgamma VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry RAB GEFs exchange GTP for GDP on RABs RUNX2 regulates genes involved in cell migration Regulation of PTEN stability and activity FLT3 Signaling Regulation of localization of FOXO transcription factors Estrogen-dependent nuclear events downstream of ESR-membrane signaling KEAP1-NFE2L2 pathway SARS-CoV-2 targets host intracellular signalling and regulatory pathways Regulation of MITF-M-dependent genes involved in pigmentation	N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE	Ovarian cancer Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
	AKT3	AKT serine/threonine kinase 3	Activation of BAD and translocation to mitochondria PIP3 activates AKT signaling PIP3 activates AKT signaling Downregulation of ERBB2:ERBB3 signaling AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the nucleus Negative regulation of the PI3K/AKT network AKT-mediated inactivation of FOXO1A CD28 dependent PI3K/Akt signaling Co-inhibition by CTLA4 G beta:gamma signalling through PI3Kgamma VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry RAB GEFs exchange GTP for GDP on RABs RUNX2 regulates genes involved in cell migration Regulation of PTEN stability and activity FLT3 Signaling Regulation of localization of FOXO transcription factors Estrogen-dependent nuclear events downstream of ESR-membrane signaling KEAP1-NFE2L2 pathway SARS-CoV-2 targets host intracellular signalling and regulatory pathways Transcriptional and post-translational regulation of MITF-M expression and activity
	APC	APC regulator of Wnt signaling pathway	Apoptotic cleavage of cellular proteins Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade Deactivation of the beta-catenin transactivating complex Disassembly of the destruction complex and recruitment of AXIN to the membrane Disassembly of the destruction complex and recruitment of AXIN to the membrane Signaling by GSK3beta mutants CTNNB1 S33 mutants aren't phosphorylated CTNNB1 S37 mutants aren't phosphorylated CTNNB1 S45 mutants aren't phosphorylated CTNNB1 T41 mutants aren't phosphorylated APC truncation mutants are not K63 polyubiquitinated APC truncation mutants have impaired AXIN binding AXIN missense mutants destabilize the destruction complex Truncations of AMER1 destabilize the destruction complex Ovarian tumor domain proteases		Cancer of the anal canal Familial adenomatous polyposis Gastric cancer Esophageal cancer Gallbladder cancer
	APP	amyloid beta precursor protein	Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1-dependent IKK and NF-kappa-B activation The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Gantenerumab Aducanumab Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form Lecanemab	Alzheimer's disease (AD)
	AR	androgen receptor	HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 Ub-specific processing proteases RUNX2 regulates osteoblast differentiation RUNX2 regulates osteoblast differentiation	Diethylstilbestrol Levonorgestrel Progesterone Spironolactone Flutamide Oxandrolone Fluphenazine Testosterone Mitotane Estrone Nilutamide Tamoxifen Norethisterone Drostanolone Norgestimate Nandrolone phenpropionate Ketoconazole Acetophenazine Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone propionate Oxybenzone 1-Testosterone Boldenone Calusterone Periciazine Prasterone Flufenamic acid Stanolone (R)-Bicalutamide Metribolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone acetate LGD2941 Dimethylcurcumin Oxymetholone Methyltestosterone Norelgestromin Stanozolol Tetrahydrogestrinone (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide BMS-564929 S-23 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide Andarine (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile LGD-2226 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Triclosan Nandrolone decanoate Ulipristal Enzalutamide Eugenol Dienogest Norethynodrel Norgestrel Homosalate Enzacamene Luprostiol Mibolerone Phenothiazine Gestrinone Apalutamide Clascoterone Darolutamide Esculin Ligandrol Testosterone cypionate Testosterone enanthate Testosterone undecanoate Stanolone acetate Segesterone acetate Boldenone undecylenate Echinacoside Ketodarolutamide	Spinal and bulbar muscular atrophy (SBMA); Kennedy's disease 46,XY disorders of sex development (Other), including: Persistent Mullerian duct syndrome; Hypospadias; Cryptorchidism Prostate cancer 46,XY disorders of sex development (Disorders in androgen synthesis or action), including: Congenital adrenal hyperplasias; Leydig cell hypoplasia; Androgen insensitivity syndrome (AIS)
	ARRB1	arrestin beta 1	Activated NOTCH1 Transmits Signal to the Nucleus G alpha (s) signalling events Lysosome Vesicle Biogenesis Golgi Associated Vesicle Biogenesis Thrombin signalling through proteinase activated receptors (PARs) Activation of SMO Activation of SMO MAP2K and MAPK activation Ub-specific processing proteases Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis Signaling downstream of RAS mutants Signaling by RAF1 mutants TGFBR3 regulates TGF-beta signaling
	ASRGL1	asparaginase and isoaspartyl peptidase 1	Phenylalanine metabolism	Aspartic acid Asparagine
	ATP5IF1	ATP synthase inhibitory factor subunit 1
	ATXN3	ataxin 3	Josephin domain DUBs FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes		Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)
	AURKA	aurora kinase A	APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Regulation of PLK1 Activity at G2/M Transition SUMOylation of DNA replication proteins TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest Regulation of TP53 Activity through Phosphorylation FBXL7 down-regulates AURKA during mitotic entry and in early mitosis AURKA Activation by TPX2 Interaction between PHLDA1 and AURKA	Phosphonothreonine AT9283 CYC116 Alisertib SNS-314 Cenisertib Enzastaurin 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE AKI-001 1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea 1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide 2-(1H-pyrazol-3-yl)-1H-benzimidazole N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE Fostamatinib MK-5108 MLN8054
	AXIN1	axin 1	Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade TCF dependent signaling in response to WNT Degradation of AXIN Disassembly of the destruction complex and recruitment of AXIN to the membrane Disassembly of the destruction complex and recruitment of AXIN to the membrane Signaling by GSK3beta mutants CTNNB1 S33 mutants aren't phosphorylated CTNNB1 S37 mutants aren't phosphorylated CTNNB1 S45 mutants aren't phosphorylated CTNNB1 T41 mutants aren't phosphorylated APC truncation mutants have impaired AXIN binding AXIN missense mutants destabilize the destruction complex Truncations of AMER1 destabilize the destruction complex Ub-specific processing proteases RUNX1 regulates estrogen receptor mediated transcription RUNX1 regulates transcription of genes involved in WNT signaling Estrogen-dependent gene expression	1,4-Dithiothreitol	Caudal duplication anomaly Hepatocellular carcinoma
	AXIN2	axin 2	TCF dependent signaling in response to WNT Binding of TCF/LEF:CTNNB1 to target gene promoters Degradation of AXIN Ub-specific processing proteases		Oligodontia-colorectal cancer syndrome Tooth agenesis; Hypodontia

Search Results for: GSK3B